U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H27FN2O4
Molecular Weight 426.4806
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ILOPERIDONE

SMILES

COC1=CC(=CC=C1OCCCN2CCC(CC2)C3=NOC4=CC(F)=CC=C34)C(C)=O

InChI

InChIKey=XMXHEBAFVSFQEX-UHFFFAOYSA-N
InChI=1S/C24H27FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-15,17H,3,8-13H2,1-2H3

HIDE SMILES / InChI
Molecular Formula C24H27FN2O4
Molecular Weight 426.4806
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022192s015lbl.pdf

Iloperidone, also known as Fanapt, Fanapta, and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia. Iloperidone shows high affinity and maximal receptor occupancy for dopamine D2 receptors in the caudate nucleus and putamen of the brains of schizophrenic patients. The improvement in cognition is attributed to iloperidone's high affinity for α adrenergic receptors. Iloperidone also binds with high affinity to serotonin 5-HT2a and dopamine 3 receptors. Iloperidone binds with moderate affinity to dopamine D4, serotonin 5-HT6 and 5-HT7, and norepinephrine NEα1 receptors. Furthermore, iloperidone binds with weak affinity to serotonin 5-HT1A, dopamine D1, and histamine H1 receptors. Iloperidone is indicated for the treatment of acute schizophrenia.

CNS Activity

Originator

Approval Year

2009
330
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2737
 110.0 nM [IC50]
Antagonist
2737
 0.4 nM [IC50]
Antagonist
2737
 210.0 nM [IC50]
Antagonist
2737
 0.4 nM [IC50]
Inhibitor
8146
 161.0 nM [IC50]
Antagonist
2737
 0.011 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8307
FANAPT

Approved Use

FANAPT is an atypical antipsychotic indicated for the treatment of schizophrenia in adults.

Launch Date

1.24148161E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2.79 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21034370/
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ILOPERIDONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
29.4 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21034370/
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ILOPERIDONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
17.6 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21034370/
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ILOPERIDONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
18 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022192s018s021lbl.pdf
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ILOPERIDONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
5%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21034370/
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ILOPERIDONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022192s018s021lbl.pdf
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ILOPERIDONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
32 mg 1 times / day multiple, oral
MTD
Dose: 32 mg, 1 times / day
Route: oral
Route: multiple
Dose: 32 mg, 1 times / day
Sources:
https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1527-3458.1997.tb00320.x
https://pubmed.ncbi.nlm.nih.gov/20368905
unhealthy, 18 - 55
n = 24
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 18 - 55
Population Size: 24
Sources:
https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1527-3458.1997.tb00320.x
https://pubmed.ncbi.nlm.nih.gov/20368905
Sources:
https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1527-3458.1997.tb00320.x
https://pubmed.ncbi.nlm.nih.gov/20368905
24 mg 1 times / day multiple, oral
Highest studied dose
Dose: 24 mg, 1 times / day
Route: oral
Route: multiple
Dose: 24 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/28817490
Page: p.3
unhealthy, 42 (13.1)
n = 31
Health Status: unhealthy
Condition: Bipolar Disorder
Age Group: 42 (13.1)
Sex: M+F
Population Size: 31
Sources:
https://pubmed.ncbi.nlm.nih.gov/28817490
Page: p.3
Sources:
https://pubmed.ncbi.nlm.nih.gov/28817490
Page: p.3
438 mg multiple, oral (total)
Overdose
Dose: 438 mg
Route: oral
Route: multiple
Dose: 438 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.17
unhealthy
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.17
Other AEs: Extrapyramidal symptoms, Electrocardiogram QTc interval prolonged...
Other AEs:
Extrapyramidal symptoms
Electrocardiogram QTc interval prolonged
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.17
576 mg single, oral
Overdose
Dose: 576 mg
Route: oral
Route: single
Dose: 576 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.17
unhealthy
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.17
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.17
10 mg 2 times / day multiple, oral
Recommended
Dose: 10 mg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.9
unhealthy
n = 874
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 874
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.9
Other AEs: Somnolence...
Other AEs:
Somnolence (11.9%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.9
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
Other AEs: Orthostatic hypotension...
Other AEs:
Orthostatic hypotension (5%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
Other AEs: Weight gain...
Other AEs:
Weight gain (18%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
12 mg 2 times / day multiple, oral
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.8
unhealthy
n = 3210
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 3210
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.8
Other AEs: Gynecomastia, Galactorrhea...
Other AEs:
Gynecomastia (0.1%)
Galactorrhea (0.2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.8
12 mg 2 times / day multiple, oral
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.8
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.8
Other AEs: Hyperprolactinemia...
Other AEs:
Hyperprolactinemia (26%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.8
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
unhealthy
n = 1344
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 1344
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
Other AEs: Syncope...
Other AEs:
Syncope (0.4%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
unhealthy
n = 1344
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 1344
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
Other AEs: Seizures...
Other AEs:
Seizures (0.1%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
Other AEs: Leukopenia, Neutropenia...
Other AEs:
Leukopenia
Neutropenia
Agranulocytosis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.8
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.8
Other AEs: Temperature regulation disorder, Dysphagia...
Other AEs:
Temperature regulation disorder
Dysphagia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.8
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.9
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.9
Other AEs: Suicide attempt, Priapism...
Other AEs:
Suicide attempt
Priapism
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.9
12 mg 2 times / day multiple, oral
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.4
unhealthy
n = 160
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 160
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.4
Other AEs: QT interval prolonged...
Other AEs:
QT interval prolonged
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.4
12 mg 2 times / day multiple, oral
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.5
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.5
Other AEs: Neuroleptic malignant syndrome...
Other AEs:
Neuroleptic malignant syndrome
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.5
12 mg 2 times / day multiple, oral
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.6
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.6
Other AEs: Tardive dyskinesia, Hyperglycemia...
Other AEs:
Tardive dyskinesia
Hyperglycemia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.6
AEs

AEs

AESignificanceDosePopulation
Electrocardiogram QTc interval prolonged
438 mg multiple, oral (total)
Overdose
Dose: 438 mg
Route: oral
Route: multiple
Dose: 438 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.17
unhealthy
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.17
Extrapyramidal symptoms
438 mg multiple, oral (total)
Overdose
Dose: 438 mg
Route: oral
Route: multiple
Dose: 438 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.17
unhealthy
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.17
Somnolence 11.9%
10 mg 2 times / day multiple, oral
Recommended
Dose: 10 mg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.9
unhealthy
n = 874
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 874
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.9
Orthostatic hypotension 5%
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
Weight gain 18%
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
Gynecomastia 0.1%
12 mg 2 times / day multiple, oral
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.8
unhealthy
n = 3210
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 3210
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.8
Galactorrhea 0.2%
12 mg 2 times / day multiple, oral
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.8
unhealthy
n = 3210
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 3210
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.8
Hyperprolactinemia 26%
12 mg 2 times / day multiple, oral
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.8
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.8
Syncope 0.4%
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
unhealthy
n = 1344
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 1344
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
Seizures 0.1%
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
unhealthy
n = 1344
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 1344
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
Agranulocytosis
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
Leukopenia
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
Neutropenia
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.7
Dysphagia
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.8
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.8
Temperature regulation disorder
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.8
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.8
Priapism
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.9
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.9
Suicide attempt
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.9
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.9
QT interval prolonged
12 mg 2 times / day multiple, oral
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.4
unhealthy
n = 160
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 160
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.4
Neuroleptic malignant syndrome
12 mg 2 times / day multiple, oral
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.5
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.5
Hyperglycemia
12 mg 2 times / day multiple, oral
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.6
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.6
Tardive dyskinesia
12 mg 2 times / day multiple, oral
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.6
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf
Page: p.6
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1670

inducer
753

inhibitor
1532
substrate
985

inhibitor
1695

inducer
372
substrate
1168

inhibitor
1789
inhibitor
1570

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A1
104

CYP1A2
1463

CYP2A6
670

CYP2B6
770

CYP2C8
869

CYP2E1
846

P-gp
1401
CYP1A1
344

CYP1A2
1013

CYP2A6
510

CYP2B6
648

CYP2C8
670

CYP2C19
955

CYP2E1
633

P-gp
1491
CYP1A2
671

CYP2C8
163

CYP2C19
283

CYP3A5
76
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A1
206
 no
CYP1A2
1620
 no
CYP1A2
1620
 no
CYP2A6
702
 no
CYP2B6
946
 no
CYP2C19
1484
 no
CYP2C8
923
 no
CYP2C8
923
 no
CYP2C9
1747
 no
CYP2C9
1747
 no
CYP2E1
929
 no
CYP3A4
1857
 no
CYP3A5
130
 no
CYP2D6
1826
 unlikely
weak (co-administration study)
Comment: 17% increase in total exposure and a 26% increase in the maximum plasma concentrations Cmax of dextromethorphan;
Page: 16.0
CYP3A4
1857
 unlikely
weak (co-administration study)
Comment: a less than 50% increase in midazolam total exposure at iloperidone steady state (14 days of oral dosing at up to 10 mg iloperidone twice daily) and no effect on midazolam Cmax;
Page: 16.0
P-gp
1588
 weak
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP1A1
344
 no
CYP1A2
1013
 no
CYP2A6
510
 no
CYP2B6
648
 no
CYP2C19
955
 no
CYP2C8
670
 no
CYP2C9
985
 no
CYP2E1
633
 no
P-gp
1491
 no
CYP3A4
1670
 yes
yes (co-administration study)
Comment: administration of ketoconazole (CYP3A4 inhibitor) increased AUC of iloperidone by 57%; administration with paroxetine AND ketoconazole resulted in a 1.4 fold increase in steady-state concentration of iloperidone;
Page: 15.0
CYP2D6
1168
 yes
yes (pharmacogenomic study)
Comment: pharmacogenic study?; administration of fluoxetine (potent inhibitor of CYP2D6) increased AUC of iloperidone by about 2- to 3-fold; administration of paroxetine (potent inhibitor of CYP2D6) increased mean steady-state peak concentrations of iloperidone by about 1.6 fold; administration with paroxetine AND ketoconazole resulted in a 1.4 fold increase in steady-state concentration of iloperidone;
Page: 15.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1603
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:65173
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:65173
ChemicalBook
CB4772066
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4772066
MolPort
MolPort-005-934-272
https://www.molport.com/shop/molecule-link/MolPort-005-934-272
Selleck Chemicals
Iloperidone(Fanapt)
http://www.selleckchem.com/products/Iloperidone(Fanapt).html
ZINC
ZINC000001548097
http://zinc15.docking.org/substances/ZINC000001548097
eMolecules
2726053
https://www.emolecules.com/cgi-bin/more?vid=2726053
PubMed

PubMed

TitleDatePubMed
The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs.
1989
3-[[(Aryloxy)alkyl]piperidinyl]-1,2-benzisoxazoles as D2/5-HT2 antagonists with potential atypical antipsychotic activity: antipsychotic profile of iloperidone (HP 873).
1995 Mar 31
The pharmacological profile of iloperidone, a novel atypical antipsychotic agent.
1995 Sep
Iloperidone binding to human and rat dopamine and 5-HT receptors.
1996 Dec 19
Iloperidone (Hoechst Marion Roussel Inc).
1999 Jun
Treatments for chronic psychosis.
2001 Dec
Iloperidone (Novartis).
2002 Jan
New antipsychotic agents for schizophrenia: pharmacokinetics and metabolism update.
2002 Jul
Gateways to clinical trials.
2002 Nov
Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism.
2002 Nov 29
Effects of clozapine, haloperidol and iloperidone on neurotransmission and synaptic plasticity in prefrontal cortex and their accumulation in brain tissue: an in vitro study.
2003
alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs.
2003 Feb 21
Functional characterization of the novel antipsychotic iloperidone at human D2, D3, alpha 2C, 5-HT6, and 5-HT1A receptors.
2003 Jul 18
Differential effects of iloperidone, clozapine, and haloperidol on working memory of rats in the delayed non-matching-to-position paradigm.
2003 Sep
Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions.
2004 Feb
Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats.
2006 Sep
Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies.
2008 Apr
Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
2008 Apr
Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
2008 Apr
Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
2008 Apr
New advances in the treatment of schizophrenia. Introduction.
2008 Apr
Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market?
2008 Jan
Gateways to clinical trials. July-August 2008.
2008 Jul-Aug
American psychiatric association.
2008 Jun
Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial.
2008 Mar
Gateways to clinical trials.
2008 Oct
Further characterization of the discriminative stimulus properties of the atypical antipsychotic drug clozapine in C57BL/6 mice: role of 5-HT(2A) serotonergic and alpha (1) adrenergic antagonism.
2009 Apr
Genome-wide association studies in pharmacogenomics: untapped potential for translation.
2009 Apr 28
Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic.
2009 Aug
Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study.
2009 Aug
Iloperidone: a new option for the treatment of schizophrenia.
2009 Dec
Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia.
2009 Jun
Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia.
2009 Nov
Iloperidone: in schizophrenia.
2009 Oct
Iloperidone for the treatment of schizophrenia.
2010 Aug
Iloperidone for schizophrenia.
2010 Aug
A review of new atypical antipsychotic launches in the United States.
2010 Dec
Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion.
2010 Dec
New atypical antipsychotics for schizophrenia: iloperidone.
2010 Feb 18
Iloperidone (Fanapt)--another second-generation antipsychotic.
2010 Feb 22
Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone.
2010 Feb 28
Gateways to clinical trials.
2010 Jan-Feb
New drugs: asenapine, iloperidone, and bepotastine besilate.
2010 Jan-Feb
Atypical antipsychotic metabolism and excretion.
2010 Jul
Iloperidone for the treatment of schizophrenia.
2010 May
Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic.
2010 May
The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis.
2010 Oct
New antipsychotic drugs: how do their receptor-binding profiles compare?
2010 Sep
Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults.
2013 Jan
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
2013 Nov
Patents

Patents

05571814
10
05580875
7
05580890
9
05580891
6
JP2011508765A
9

Sample Use Guides

In Vivo Use Guide
The recommended target dosage is 12 to 24 mg/day administered twice daily. This target dosage range is achieved by daily dosage adjustments, alerting patients to symptoms of orthostatic hypotension, starting at a dose of 1 mg twice daily, then moving to 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg twice daily on Days 2, 3, 4, 5, 6, and 7 respectively, to reach the 12 mg/day to 24 mg/day dose range.
Route of Administration: Oral
In Vitro Use Guide
While pacing the hearts at stimulation cycle lengths of 200 or 250 ms, or during natural sinus rhythm (no external pacing), iloperidone 100 nmol/L prolonged MAPD(90) by respectively 9.2 ± 0.9, 11.2 ± 1.6 and 21.4 ± 2.3 ms.
Substance Class Chemical
Created
by admin
on Fri Dec 16 17:52:53 UTC 2022
Edited
by admin
on Fri Dec 16 17:52:53 UTC 2022
Record UNII
VPO7KJ050N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ILOPERIDONE
DASH   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
ILOPERIDONE [VANDF]
Common Name English
HP-873
Code English
ILOPERIDONE [USAN]
Common Name English
4'-(3-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)PIPERIDINO)PROPOXY)-3'-METHOXYACETOPHENONE
Systematic Name English
ILOPERIDONE [ORANGE BOOK]
Common Name English
Iloperidone [WHO-DD]
Common Name English
ILOPERIDONE [MART.]
Common Name English
HP 873
Code English
ETHANONE, 1-(4-(3-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-PIPERIDINYL)PROPOXY)-3-METHOXYPHENYL)-
Systematic Name English
iloperidone [INN]
Common Name English
ILOPERIDONE [USP-RS]
Common Name English
FANAPT
Brand Name English
ILOPERIDONE [MI]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175430
Created by admin on Fri Dec 16 17:52:53 UTC 2022 , Edited by admin on Fri Dec 16 17:52:53 UTC 2022
LIVERTOX NBK548669
Created by admin on Fri Dec 16 17:52:53 UTC 2022 , Edited by admin on Fri Dec 16 17:52:53 UTC 2022
WHO-VATC QN05AX14
Created by admin on Fri Dec 16 17:52:53 UTC 2022 , Edited by admin on Fri Dec 16 17:52:53 UTC 2022
NCI_THESAURUS C29710
Created by admin on Fri Dec 16 17:52:53 UTC 2022 , Edited by admin on Fri Dec 16 17:52:53 UTC 2022
WHO-ATC N05AX14
Created by admin on Fri Dec 16 17:52:53 UTC 2022 , Edited by admin on Fri Dec 16 17:52:53 UTC 2022
Code System Code Type Description
CHEBI
65173
Created by admin on Fri Dec 16 17:52:53 UTC 2022 , Edited by admin on Fri Dec 16 17:52:53 UTC 2022
PRIMARY
DRUG BANK
DB04946
Created by admin on Fri Dec 16 17:52:53 UTC 2022 , Edited by admin on Fri Dec 16 17:52:53 UTC 2022
PRIMARY
EVMPD
SUB08135MIG
Created by admin on Fri Dec 16 17:52:53 UTC 2022 , Edited by admin on Fri Dec 16 17:52:53 UTC 2022
PRIMARY
WIKIPEDIA
Iloperidone
Created by admin on Fri Dec 16 17:52:53 UTC 2022 , Edited by admin on Fri Dec 16 17:52:53 UTC 2022
PRIMARY
LACTMED
Iloperidone
Created by admin on Fri Dec 16 17:52:53 UTC 2022 , Edited by admin on Fri Dec 16 17:52:53 UTC 2022
PRIMARY
DAILYMED
VPO7KJ050N
Created by admin on Fri Dec 16 17:52:53 UTC 2022 , Edited by admin on Fri Dec 16 17:52:53 UTC 2022
PRIMARY
ChEMBL
CHEMBL14376
Created by admin on Fri Dec 16 17:52:53 UTC 2022 , Edited by admin on Fri Dec 16 17:52:53 UTC 2022
PRIMARY
INN
7045
Created by admin on Fri Dec 16 17:52:53 UTC 2022 , Edited by admin on Fri Dec 16 17:52:53 UTC 2022
PRIMARY
MERCK INDEX
M6211
Created by admin on Fri Dec 16 17:52:53 UTC 2022 , Edited by admin on Fri Dec 16 17:52:53 UTC 2022
PRIMARY Merck Index
NCI_THESAURUS
C83784
Created by admin on Fri Dec 16 17:52:53 UTC 2022 , Edited by admin on Fri Dec 16 17:52:53 UTC 2022
PRIMARY
EPA CompTox
DTXSID6049060
Created by admin on Fri Dec 16 17:52:53 UTC 2022 , Edited by admin on Fri Dec 16 17:52:53 UTC 2022
PRIMARY
PUBCHEM
71360
Created by admin on Fri Dec 16 17:52:53 UTC 2022 , Edited by admin on Fri Dec 16 17:52:53 UTC 2022
PRIMARY
RS_ITEM_NUM
1336249
Created by admin on Fri Dec 16 17:52:53 UTC 2022 , Edited by admin on Fri Dec 16 17:52:53 UTC 2022
PRIMARY
CAS
133454-47-4
Created by admin on Fri Dec 16 17:52:53 UTC 2022 , Edited by admin on Fri Dec 16 17:52:53 UTC 2022
PRIMARY
HSDB
8207
Created by admin on Fri Dec 16 17:52:53 UTC 2022 , Edited by admin on Fri Dec 16 17:52:53 UTC 2022
PRIMARY
RXCUI
73178
Created by admin on Fri Dec 16 17:52:53 UTC 2022 , Edited by admin on Fri Dec 16 17:52:53 UTC 2022
PRIMARY RxNorm
MESH
C081732
Created by admin on Fri Dec 16 17:52:53 UTC 2022 , Edited by admin on Fri Dec 16 17:52:53 UTC 2022
PRIMARY
USAN
EE-25
Created by admin on Fri Dec 16 17:52:53 UTC 2022 , Edited by admin on Fri Dec 16 17:52:53 UTC 2022
PRIMARY
FDA UNII
VPO7KJ050N
Created by admin on Fri Dec 16 17:52:53 UTC 2022 , Edited by admin on Fri Dec 16 17:52:53 UTC 2022
PRIMARY
DRUG CENTRAL
3294
Created by admin on Fri Dec 16 17:52:53 UTC 2022 , Edited by admin on Fri Dec 16 17:52:53 UTC 2022
PRIMARY
IUPHAR
87
Created by admin on Fri Dec 16 17:52:53 UTC 2022 , Edited by admin on Fri Dec 16 17:52:53 UTC 2022
PRIMARY
Related Record Type Details
5-HYDROXYTRYPTAMINE RECEPTOR 2A
TARGET -> INHIBITOR
MAJOR
Ki
Structure of ILOPERIDONE
EXCRETED UNCHANGED
Iloperidone counted 0.7 % of dose in excreta from all six human subjects following a single oral dose of 3 mg 14C ILO522.
D(3) DOPAMINE RECEPTOR
TARGET -> INHIBITOR
MAJOR
Ki
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
CYTOCHROME P450 2D6
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
D(2) DOPAMINE RECEPTOR
TARGET -> INHIBITOR
MAJOR
Ki
Related Record Type Details
Structure of 1-(4-(3-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-PIPERIDINYL)PROPOXY)-3-METHOXYPHENYL)-2-HYDROXYETHANONE
METABOLITE -> PARENT
Structure of 1-(4-(3-(4-(6-FLUORO-1,2-BENZOXAZOL-3-YL)-1-PIPERIDYL)PROPOXY)-3-METHOXY-PHENYL)ETHANE-1,2-DIOL
METABOLITE -> PARENT
This metabolite counted 4.8 % of dose in excreta from all six human subjects following a single oral dose of 3 mg 14C ILO522.
MINOR
Structure of 3-(4-ACETYL-2-METHOXYPHENOXY)PROPANOIC ACID
METABOLITE -> PARENT
This metabolite counted 6.5 % of dose in excreta from all six human subjects following a single oral dose of 3 mg 14C ILO522.
Structure of P-88-8991, (-)-
METABOLITE -> PARENT
Structure of PHENOL, 4-(3-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-PIPERIDINYL)PROPOXY)-3-METHOXY-
METABOLITE -> PARENT
Structure of (2S,3S,4S,5R,6R)-6-(1-(4-(3-(4-(6-FLUORO-1,2-BENZOXAZOL-3-YL)-1-PIPERIDYL)PROPOXY)-3-METHOXY-PHENYL)ETHOXY)-3,4,5-TRIHYDROXY-TETRAHYDROPYRAN-2-CARBOXYLIC ACID
METABOLITE -> PARENT
This metabolite counted 1.5 % of dose in excreta from all six human subjects following a single oral dose of 3 mg 14C IL0522.
Structure of 1-(4-(3-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-OXIDO-1-PIPERIDINYL)PROPOXY)-3-METHOXYPHENYL)ETHANONE
METABOLITE -> PARENT
This metabolite counted 0.4 % of dose in excreta from all six human subjects following a single oral dose of 3 mg 14C ILO522.
MINOR
Structure of 2-(4-(3-(4-(6-FLUORO-1,2-BENZOXAZOL-3-YL)-1-PIPERIDYL)PROPOXY)-3-METHOXY-PHENYL)-2-HYDROXY-ACETIC ACID
METABOLITE -> PARENT
This metabolite counted <3.1 % of dose in excreta from all six human subjects following a single oral dose of 3 mg 14C ILO522.
MINOR
Structure of (2S,3S,4S,5R,6S)-6-(4-(3-(4-(6-FLUORO-1,2-BENZOXAZOL-3-YL)-1-PIPERIDYL)PROPOXY)-3-METHOXY-PHENOXY)-3,4,5-TRIHYDROXY-TETRAHYDROPYRAN-2-CARBOXYLIC ACID
METABOLITE -> PARENT
Structure of 4-(3-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-PIPERIDINYL)PROPOXY)-3-METHOXYBENZOIC ACID
METABOLITE -> PARENT
FECAL; URINE
Structure of 1-(4-(3-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-PIPERIDINYL)PROPOXY)-3-HYDROXYPHENYL)ETHANONE
METABOLITE -> PARENT
MINOR
Structure of (4-FLUORO-2-HYDROXY-PHENYL)-(1-(3-(4-HYDROXY-2-METHOXY-PHENOXY)PROPYL)-4-PIPERIDYL)METHANONE
METABOLITE -> PARENT
Structure of P-88-8991
METABOLITE ACTIVE -> PARENT
The active metabolite P88 accounts for 19.5% and 34.0% of total plasma exposure in EM and PM, respectively.
MAJOR
PLASMA; URINE
Related Record Type Details
Structure of 4-(3-CHLOROPROPOXY)-3-METHOXYACETOPHENONE
IMPURITY -> PARENT
Related Record Type Details
Structure of ILOPERIDONE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC HIGH-FAT MEAL

FED CONDITION

ORAL ADMINISTRATION

Tmax PHARMACOKINETIC ORAL ADMINISTRATION

NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966